US Patent Issued to Blueprint Medicines on June 16 for "Heterocyclic EGFR inhibitors for use in the treatment of cancer" (Massachusetts Inventors)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,655,129, issued on June 16, was assigned to Blueprint Medicines Corp. (Cambridge, Mass.).

"Heterocyclic EGFR inhibitors for use in the treatment of cancer" was invented by Natasja Brooijmans (Cambridge, Mass.), John Emmerson Campbell (Cambridge, Mass.), Christopher De Savi (Cambridge, Mass.), Thomas A. Dineen (Cambridge, Mass.), Meredith Suzanne Eno (Cambridge, Mass.), Joseph L. Kim (Cambridge, Mass.), Aysegul Ozen (Cambridge, Mass.), Emanuele Perola (Cambridge, Mass.), Brett D. Williams (Cambridge, Mass.), Douglas Wilson (Cambridge, Mass.) and Kevin J. Wilson (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provid...